PHQ-9 Depression Screening Test - Mental Health Assessment

What is it?

The Patient Health Questionnaire-9 (PHQ-9) is a widely used, validated screening tool designed to assess the presence and severity of depression based on the diagnostic criteria for major depressive disorder from the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition). Developed by Drs. Robert Spitzer, Janet Williams, and Kurt Kroenke in 1999, the PHQ-9 consists of nine questions that correspond directly to the nine DSM criteria for diagnosing major depression. Each question asks about symptoms experienced over the past two weeks, including depressed mood, loss of interest or pleasure (anhedonia), sleep disturbances, fatigue, appetite changes, feelings of worthlessness or guilt, difficulty concentrating, psychomotor agitation or retardation, and thoughts of death or self-harm. Respondents rate each symptom on a scale from 0 (not at all) to 3 (nearly every day), yielding a total score ranging from 0 to 27. The PHQ-9 is brief, taking only 2-3 minutes to complete, making it practical for use in primary care settings, mental health clinics, research studies, and even self-assessment. Scores are interpreted as follows: 0-4 indicates minimal or no depression, 5-9 suggests mild depression, 10-14 indicates moderate depression, 15-19 suggests moderately severe depression, and 20-27 indicates severe depression. Beyond screening, the PHQ-9 can be used to monitor treatment response over time, as decreasing scores indicate symptom improvement. A unique and critical feature of the PHQ-9 is question 9, which directly assesses suicidal ideation by asking about thoughts of being better off dead or of hurting oneself. Any positive response to this question warrants immediate further evaluation and safety planning, regardless of the total score.

Formula Details

The PHQ-9 consists of 9 questions derived directly from the DSM-V diagnostic criteria for Major Depressive Disorder. Each question asks how often a symptom has occurred in the past 2 weeks, scored on a 4-point scale: 0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day. The total score is the simple arithmetic sum of all 9 item scores, producing a range of 0 to 27 that maps onto validated severity categories. Developed by Dr. Kurt Kroenke and Dr. Robert Spitzer in 2001, the PHQ-9 has been validated in numerous clinical and population-based studies showing high sensitivity (>85%) and strong specificity for detecting depression across diverse settings. Question 9 specifically screens for suicidal ideation and thoughts of self-harm, and any positive response on that item warrants immediate clinical assessment regardless of the total score.

How to Calculate

Calculating the PHQ-9 score is straightforward and involves summing the individual item scores. The questionnaire contains nine items, each corresponding to a DSM-IV criterion for major depressive disorder. For each question, respondents indicate how often they have been bothered by each symptom over the past two weeks using the following scale: 0 = Not at all, 1 = Several days, 2 = More than half the days, 3 = Nearly every day. The nine symptoms assessed are: (1) Little interest or pleasure in doing things, (2) Feeling down, depressed, or hopeless, (3) Trouble falling or staying asleep, or sleeping too much, (4) Feeling tired or having little energy, (5) Poor appetite or overeating, (6) Feeling bad about yourself - or that you are a failure or have let yourself or your family down, (7) Trouble concentrating on things, such as reading the newspaper or watching television, (8) Moving or speaking so slowly that other people could have noticed, or being so fidgety or restless that you have been moving around a lot more than usual, (9) Thoughts that you would be better off dead, or of hurting yourself in some way. To obtain the total PHQ-9 score, simply add up the scores for all nine questions. For example, if a person answers: 2, 2, 1, 3, 1, 2, 1, 0, 0, the total score would be 2+2+1+3+1+2+1+0+0 = 12, indicating moderate depression. In addition to the total score, clinicians often assess functional impairment using a tenth question (not counted in the score) that asks how difficult the symptoms have made it to work, take care of things at home, or get along with others. Response options are: not difficult at all, somewhat difficult, very difficult, or extremely difficult. The presence of functional impairment, combined with the total score, helps determine the clinical significance of depressive symptoms and guides treatment decisions.

BMI Range	Category	Description
0 – 4	Minimal or None	No clinically significant depressive symptoms detected. Continue a healthy lifestyle and schedule regular check-ins with a healthcare provider if personal risk factors are present.
5 – 9	Mild Depression	Mild depressive symptoms have been detected. Lifestyle changes, strengthening social support networks, and close monitoring of symptoms are recommended. Discussing results with a healthcare provider is advised.
10 – 14	Moderate Depression	Moderate depressive symptoms are present, requiring professional evaluation. A thorough clinical assessment and individualized treatment plan should be discussed with your doctor or a mental health specialist.
15 – 19	Moderately Severe	Significant depressive symptoms have been identified. Prompt clinical attention and likely referral to dedicated mental health services are strongly recommended for appropriate care.
20 – 27	Severe Depression	Severe symptoms indicate a high level of functional and emotional impairment. Immediate professional help is essential. Please reach out to a healthcare provider or a crisis support line today without delay.

Interpretation

PHQ-9 scores are interpreted according to established severity ranges that have been validated in numerous studies across diverse populations. A score of 0-4 indicates minimal or no depression, suggesting that the individual is likely not experiencing clinically significant depressive symptoms. Scores of 5-9 suggest mild depression, which may benefit from watchful waiting, patient education, and follow-up reassessment in 2-4 weeks. If symptoms persist or worsen, treatment such as psychotherapy may be considered. Scores of 10-14 indicate moderate depression, typically warranting active treatment with psychotherapy (such as cognitive behavioral therapy or interpersonal therapy), antidepressant medication, or both, depending on patient preference and clinical judgment. Scores of 15-19 suggest moderately severe depression, which generally requires active treatment combining both medication and psychotherapy for optimal outcomes. Scores of 20-27 indicate severe depression, necessitating immediate initiation of pharmacotherapy and/or psychotherapy, and consideration of specialty mental health referral or even hospitalization if there is acute safety risk. It is crucial to note that interpretation should never rely solely on the total score. Question 9, which assesses suicidal ideation, requires special attention. Any score greater than 0 on question 9 (indicating thoughts of death or self-harm on several days or more) should trigger immediate suicide risk assessment, safety planning, and appropriate intervention, potentially including emergency psychiatric evaluation, regardless of the overall score. Additionally, the PHQ-9 should be interpreted in clinical context, considering factors such as recent life stressors, medical conditions that can mimic or contribute to depression (hypothyroidism, anemia, chronic pain, neurological disorders), substance use, and response to previous treatments. The PHQ-9 is a screening tool, not a diagnostic instrument - a positive screen should lead to comprehensive clinical assessment to confirm the diagnosis and develop an individualized treatment plan.

Limitations

The PHQ-9 is a screening tool, not a diagnostic instrument, and it cannot diagnose depression or rule out other mental health conditions on its own. Scores can be influenced by medical conditions that share symptoms with depression, including chronic pain, thyroid disorders, sleep disorders, and substance use disorders, which may inflate the total score without true major depressive disorder being present. The questionnaire captures a 2-week snapshot of symptoms and does not assess symptom duration, which is clinically important because a formal diagnosis of major depressive disorder typically requires symptoms lasting at least 2 weeks in a row. Cultural factors may affect how individuals interpret and respond to the questions, potentially leading to under- or over-reporting of symptoms. The PHQ-9 does not screen for bipolar disorder, which shares some symptoms with depression but requires a fundamentally different treatment approach. As a self-report instrument, its accuracy depends entirely on the respondent's self-awareness and willingness to answer honestly. PHQ-9 results should always be interpreted by a qualified healthcare professional within the context of a comprehensive clinical assessment.

Health Risks

Untreated depression carries serious and wide-ranging health consequences that affect both mental and physical wellbeing. **Suicide Risk:** Suicidal ideation and self-harm represent the most urgent risks, and question 9 of the PHQ-9 specifically screens for this concern - any positive response requires immediate professional intervention and safety planning. Men with depression are 3-4 times more likely to die by suicide than women, despite lower depression rates, due to using more lethal means and delaying help-seeking. Older adults with depression also have elevated suicide risk, particularly older white men. Young adults (18-25) have increasing suicide rates, making screening critical. **Cardiovascular Disease:** Depression independently doubles the risk of heart attack and stroke, with particularly strong associations in middle-aged and older adults. Women with depression have higher cardiovascular risk than expected, especially post-menopause. Depression worsens outcomes after heart attack and reduces medication adherence. **Physical Health Impacts:** Untreated depression weakens immune function, amplifies chronic pain perception (higher in women), accelerates aging processes, and is associated with inflammatory conditions. In older adults, depression increases risk of dementia, Alzheimer's disease, Parkinson's disease, and overall mortality. **Substance Use:** Depression increases vulnerability to alcohol and drug abuse, with men more likely to self-medicate with substances than women. Young adults with depression have particularly high rates of co-occurring substance use disorders. **Reproductive Health:** In women, depression during pregnancy (perinatal depression) increases risk of preterm birth, low birth weight, and postpartum depression. Untreated postpartum depression affects mother-infant bonding and child development. **Social and Occupational:** Depression promotes social isolation (especially concerning in older adults), relationship breakdown, job loss, reduced work productivity, and financial problems. In young adults, depression impairs academic performance and career development. **Progression:** Left untreated, depression tends to worsen, become chronic, and grow progressively harder to treat. First episode in young adulthood often leads to recurrent episodes throughout life if not properly treated. Early intervention is critical for preventing chronicity and improving long-term outcomes across all age groups and genders. **Comorbidity:** Anxiety disorders (especially in women and young adults), PTSD (higher in women with trauma history), eating disorders (primarily young women), and substance use disorders (higher in men) frequently accompany depression and require simultaneous treatment.

Alternative Body Composition Measures

Several validated screening and assessment tools complement or serve as alternatives to the PHQ-9 for evaluating depression and related conditions. The Beck Depression Inventory (BDI) is one of the most widely used clinical depression scales in both research and practice, with strong psychometric properties and extensive normative data. The CES-D (Center for Epidemiologic Studies Depression Scale) was specifically designed for population-based epidemiological research and remains a standard in public health studies. The GAD-7 (Generalized Anxiety Disorder scale) screens for generalized anxiety, which frequently co-occurs with depression; administering both the PHQ-9 and GAD-7 together provides a substantially fuller clinical picture of a patient's mental health status. For postpartum depression specifically, the Edinburgh Postnatal Depression Scale (EPDS) is considered the gold standard due to its sensitivity to the unique symptom profile of new mothers. The Geriatric Depression Scale (GDS) was purpose-designed for older adults and avoids somatic items that may be confounded by aging. Ultimately, the most accurate and comprehensive assessment of depression remains a structured clinical interview conducted by a trained mental health professional, which can evaluate symptoms in their full individual and contextual setting.

Demographic Differences

Depression rates, risk factors, and symptom presentation differ significantly across demographic groups and populations. **Gender Differences:** Women are approximately twice as likely as men to develop depression across the lifespan (lifetime prevalence: 20-25% for women vs. 10-12% for men), with elevated risk connected to hormonal transitions including the postpartum period (10-15% postpartum depression rate), perimenopause, and menstruation-related mood changes (PMDD affects 3-8% of women). Women also have higher lifetime rates of trauma exposure (particularly sexual assault and intimate partner violence) and psychosocial stressors, including gender-based discrimination and caregiving burdens. Depression in women tends to feature more internalized symptoms such as sadness, worthlessness, and excessive guilt. Conversely, men who develop depression are 3-4 times more likely to die by suicide despite having lower overall depression prevalence, because they tend to use more lethal means and delay help-seeking due to stigma. Depression in men may manifest differently, often presenting as irritability, anger, aggression, risk-taking behaviors, and substance abuse rather than sadness - this "masked depression" can lead to underdiagnosis. Men are also more likely to somatize depression through physical complaints like chronic pain, headaches, or digestive issues. **Age-Related Differences:** Young adults aged 18 to 25 show the highest rates of depression among all age groups (17.0% in this demographic), facing unique stressors including identity formation, academic pressures, career uncertainty, relationship challenges, and social media impacts. Depression in this group is strongly linked to anxiety disorders and eating disorders. Adults aged 26-45 face work-life balance pressures, financial stress, relationship challenges, and parenting demands, with depression often co-occurring with burnout and anxiety. Middle-aged adults (46-64) experience depression often complicated by chronic health conditions, caregiving responsibilities for both children and aging parents ("sandwich generation"), career transitions, and early mortality awareness. Older adults aged 65 and above have depression that is frequently underdiagnosed because symptoms overlap with medical conditions, cognitive changes, and grief. Late-life depression is strongly associated with cardiovascular disease, stroke, dementia risk, and social isolation following retirement or loss of spouse. However, contrary to stereotypes, depression is NOT a normal part of aging and should always be treated. **Cultural Considerations:** Cultural factors meaningfully influence both the expression and the recognition of depression. Asian, Latino, and African American populations show higher rates of somatic presentation, experiencing and reporting depression primarily as physical symptoms (headaches, chest pain, fatigue, dizziness) rather than emotional distress. Some cultures lack direct vocabulary for "depression" or view mental health through spiritual/moral frameworks rather than medical ones. Stigma varies significantly by culture, with some communities viewing mental illness as shameful or a sign of weak character, which reduces help-seeking. Immigration, acculturation stress, discrimination, and language barriers create additional risk factors for depression in immigrant and minority populations. **Universal Risk Factors:** Socioeconomic disadvantage, unemployment, housing instability, food insecurity, social isolation, chronic medical illness, disability, chronic pain, history of trauma or abuse, and caregiving burden are powerful risk factors cutting across all demographic groups. The PHQ-9 has been validated in diverse populations worldwide in over 50 languages, though some studies have identified slight score variations by ethnicity that clinicians should consider during interpretation, particularly around somatic items.

Tips

Answer all questions honestly based on how you have actually been feeling over the past two weeks, not how you think you should feel or how you felt in the distant past
If question 9 (thoughts of death or self-harm) receives any score other than 0, seek immediate professional help - contact a mental health crisis line, emergency services, or go to an emergency room
The PHQ-9 can be used repeatedly to monitor symptoms over time - take it every 2-4 weeks during treatment to track whether symptoms are improving
Share your PHQ-9 results with your healthcare provider to facilitate conversation about mental health and treatment options
Remember that depression is highly treatable - effective treatments include psychotherapy (such as cognitive behavioral therapy or interpersonal therapy), medication (antidepressants), or combination approaches
A high score does not mean weakness or failure - depression is a medical condition with biological, psychological, and social components
Lifestyle factors can help manage depression alongside professional treatment: regular exercise, adequate sleep, healthy nutrition, social connection, and stress management techniques
If your score indicates moderate to severe depression, do not try to manage it alone - reach out to a mental health professional for comprehensive evaluation and treatment planning
For women: Be aware that hormonal changes (menstrual cycle, pregnancy, postpartum, menopause) can affect mood - discuss these with your healthcare provider as they may influence treatment decisions
For men: Depression is not a sign of weakness - it's a medical condition that affects millions of men. If you're experiencing irritability, anger, or risk-taking behaviors instead of typical sadness, you may still have depression
Young adults (18-25): Depression is the most common mental health condition in your age group - seeking help is a sign of strength, not weakness. Campus counseling services and young adult support groups can be valuable resources
Older adults (65+): Depression is not a normal part of aging. If you're experiencing persistent sadness, loss of interest, or physical complaints without clear medical cause, discuss depression screening with your doctor
If you have experienced trauma, discrimination, or chronic stress related to your gender, age, race, or other identity factors, specialized trauma-informed care may be particularly beneficial

Frequently Asked Questions

What score on the PHQ-9 indicates clinical depression?

While there is no absolute cutoff, a PHQ-9 score of 10 or higher is commonly used as the threshold for clinically significant depression that may warrant treatment. Scores of 10-14 suggest moderate depression, 15-19 indicate moderately severe depression, and 20-27 reflect severe depression. However, the interpretation should consider clinical context. Some individuals with scores of 8-9 may have clinically significant depression if symptoms cause substantial functional impairment or distress, while others with scores of 10-12 may not meet full diagnostic criteria for major depressive disorder if symptoms have been present for less than two weeks or if they are better explained by grief, medical illness, or situational stressors. The PHQ-9 is a screening tool that identifies individuals who need further evaluation - a comprehensive clinical assessment by a mental health professional is required to make a formal diagnosis of depression.

How often should I take the PHQ-9?

The frequency of PHQ-9 administration depends on the purpose and clinical situation. For initial screening in primary care or other settings, a single administration is sufficient to identify potential depression requiring further evaluation. For individuals undergoing treatment for depression, the PHQ-9 should be administered regularly to monitor treatment response - typically every 2-4 weeks during the acute treatment phase. Research shows that repeated measurement and feedback of PHQ-9 scores to both patients and providers improves treatment outcomes. Once depression has improved and the patient is in the maintenance phase, less frequent administration (every 2-3 months) may be appropriate to monitor for relapse. For self-monitoring, individuals may choose to complete the PHQ-9 weekly or biweekly to track their symptoms, but should always share results with their healthcare provider and not rely on self-assessment alone for treatment decisions.

Can the PHQ-9 diagnose other mental health conditions besides depression?

No, the PHQ-9 is specifically designed to screen for major depressive disorder and does not diagnose other mental health conditions. However, depression frequently co-occurs with other psychiatric disorders including anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety), post-traumatic stress disorder (PTSD), bipolar disorder, substance use disorders, and eating disorders. An elevated PHQ-9 score should prompt evaluation for these co-occurring conditions as well. Additionally, some symptoms on the PHQ-9 (such as sleep disturbance, concentration problems, and psychomotor changes) can occur in other conditions. For comprehensive mental health assessment, healthcare providers may use additional screening tools such as the GAD-7 for anxiety, the Mood Disorder Questionnaire (MDQ) for bipolar disorder, or structured clinical interviews. If you have concerns about anxiety, mood swings, trauma, or other mental health issues in addition to or instead of depression, discuss these with a mental health professional.

What should I do if I score high on question 9 about thoughts of death or self-harm?

Any positive response to question 9 (indicating thoughts of death or self-harm on several days, more than half the days, or nearly every day) requires immediate action. First, recognize that having these thoughts does not mean you are weak or broken - they are symptoms of depression that can be treated. Do not wait or try to handle these thoughts alone. Seek immediate help through one of these options: (1) Call the National Suicide Prevention Lifeline at 988 (available 24/7 in the United States), (2) Call emergency services (911), (3) Go to the nearest emergency room, (4) Contact a mental health crisis line in your area, (5) Reach out to your therapist, psychiatrist, or primary care doctor immediately. While waiting for help, stay with someone you trust and remove access to means of self-harm (firearms, medications, sharp objects). If you are supporting someone who endorsed question 9, do not leave them alone, take their thoughts seriously, listen without judgment, and help them access professional help immediately. Suicidal thoughts are a medical emergency requiring immediate professional intervention - effective treatments are available and most people who receive help can recover and go on to live fulfilling lives.

Is the PHQ-9 accurate for everyone, including different age groups and cultures?

The PHQ-9 has been extensively validated across diverse populations and has shown good reliability and validity in various age groups, cultural backgrounds, and languages. However, some considerations apply. For adolescents, a modified version called the PHQ-9 Modified for Teens (PHQ-A) may be more appropriate, as it uses language better suited to younger individuals. For elderly populations, the PHQ-9 remains valid, though some somatic symptoms (fatigue, sleep changes, appetite changes) may be more common due to aging or medical conditions, potentially leading to false positives. Cultural factors can influence symptom expression and reporting - some cultures may be more likely to report somatic symptoms (physical complaints) rather than emotional symptoms of depression, while others may have stigma around mental health that affects honest reporting. The PHQ-9 has been translated into many languages and validated in many countries, but cultural adaptation beyond simple translation may be needed for optimal performance. Despite these considerations, the PHQ-9 remains one of the most well-validated and widely applicable depression screening tools available. For specific populations or when cultural factors are relevant, interpretation should be done by clinicians familiar with cultural considerations in mental health assessment.

Why do women have higher rates of depression than men?

Women experience depression at roughly twice the rate of men due to a complex interaction of biological, psychological, and social factors. Biological factors include hormonal fluctuations throughout the menstrual cycle, pregnancy, postpartum period, and menopause - estrogen and progesterone influence neurotransmitter systems involved in mood regulation. Women also have higher rates of thyroid disorders, which can contribute to depression. Psychological and social factors include higher rates of childhood sexual abuse, intimate partner violence, and sexual assault - all strong risk factors for depression. Women face unique stressors including gender-based discrimination, wage inequality, higher caregiving burdens (for children, elderly parents, and ill family members), and the challenge of balancing multiple roles. Women are also more likely to ruminate (repeatedly think about problems) rather than distract, which can prolong depressive episodes. Additionally, women are more likely to seek help and receive diagnosis, which may partially explain statistical differences. It's important to note that while prevalence is higher in women, depression in men is seriously undertreated and men are at much higher risk of suicide, making depression screening important for all genders.

How does depression differ between younger and older adults?

Depression manifests differently across the lifespan. Young adults (18-25) typically experience depression alongside identity formation challenges, with symptoms often co-occurring with anxiety, eating disorders, and substance use. Social media, academic pressures, and relationship issues are common triggers. This age group tends to experience more acute, episodic depression with strong emotional symptoms. Middle-aged adults (26-64) often experience depression in the context of work stress, relationship problems, parenting challenges, and caregiving responsibilities. Depression may be chronic or recurrent, and frequently co-occurs with burnout, anxiety, and physical health problems. Older adults (65+) present unique challenges: depression is often underdiagnosed because symptoms overlap with medical conditions, medications, grief, and cognitive decline. Late-life depression features more somatic complaints (pain, fatigue, digestive issues), fewer expressions of sadness or guilt, and more apathy and loss of interest. Older adults are less likely to report feeling "depressed" but may describe emptiness, loss of purpose, or excessive worry about health. Depression in older adults is strongly associated with cardiovascular disease, stroke risk, dementia, and increased mortality. Importantly, depression is NOT a normal part of aging and should always be evaluated and treated. Treatment response rates are comparable across age groups, but older adults may need different treatment approaches considering medications they take for other conditions.

Are there gender-specific treatment approaches for depression?

While the core treatments for depression (psychotherapy and medication) are effective across genders, some considerations can optimize outcomes. For women, treatment planning should consider hormonal factors - antidepressants may need adjustment during menstrual cycles, pregnancy, postpartum, or menopause. Postpartum depression may benefit from mother-infant therapy in addition to individual treatment. Women may respond particularly well to interpersonal therapy (IPT) which addresses relationship issues and role transitions. For women with trauma history (higher rates than men), trauma-focused therapies like EMDR or CPT may be important. For men, addressing stigma and masculinity norms is crucial - many men view depression as weakness or fear being perceived as less masculine if they seek help. Therapy approaches that are action-oriented, problem-focused, and avoid "talking about feelings" terminology may be more acceptable initially. Men may benefit from male-specific support groups where they can discuss mental health in a comfortable environment. Physical activity interventions are highly effective for men. Men are more likely to self-medicate with alcohol or drugs, so screening for substance use is critical. Both genders benefit from treatment, but engagement strategies may need to be tailored. The most important factor is simply seeking help - depression is highly treatable regardless of gender when properly addressed.

References & Sources

[1]Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613.
[2]American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). Arlington, VA: American Psychiatric Publishing; 2013.
[3]Manea L, Gilbody S, McMillan D. Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis. CMAJ. 2012;184(3):E191-196.
[4]Kroenke K, Spitzer RL. The PHQ-9: A new depression diagnostic and severity measure. Psychiatr Ann. 2002;32(9):509-515.
[5]Löwe B, et al. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care. 2004;42(12):1194-1201.

These references are provided for educational purposes. Always consult healthcare professionals for medical advice.

PHQ-9 Depression Screening Test - Mental Health Assessment